Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Woodland Biosciences and CNBE – INRS extend oncology alliance to now include liver diseasesThe partners extend their alliance to now include NASH / Fibrosis / Fatty Liver Disease or Steatosis and their sequelae HCC, or liver cancer to augment their oncology offerings.
By: Woodland Pharmaceuticals, CNBE-INRS Liver diseases including fatty liver and diabetes are rapidly becoming one of the most pressing needs in the medical community as the population grows and ages. Our new spectrum of services comprises in vivo pharmacology studies of the progression of liver disease in mouse models. In addition to standard efficacy studies, the alliance allows us to provide the following expanded and integrated menu of services making the sponsor’s experiment a more complete study that can be customized to customer needs: screening toxicology (biodistribution, maximum tolerated dose, dose-range finding, immunotoxicology,) Further, in partnership with CNBE, Woodland and its academic partner are expanding model research and development to include a rat model of Type 2 diabetes and NASH / fibrosis to complement the current model in male C57BL6 mice. Until now model offerings from CROs around the globe offered only male mouse model of fibrosis, however exciting new data from Woodland research shows for the first time liver fibrosis in female mice. This work is offered as a developmental model for interested parties from our new research facilities in Laval, Canada or in our Massachusetts laboratories. “This exciting new field of experimental model research opens new doors into the burgeoning field of liver diseases including fibrosis, cirrhosis and liver cancer as well as the complications of obesity and diabetes such as fatty liver disease,” explains Dr. Michael R. Briggs, President of Woodland Biosciences. “Thanks to this agreement, the clients will be able to use the expertise of each organisation to strengthen their drug development pipeline. They will have also the possibility to expand their development in using the state-of-art animal facility of the CNBE having the expertise and capability to house rodents, rabbits, dogs, ferrets, farm animals (swine, sheep, goats and fowls) and non-human primates,” adds Dr. Mario C. Filion, Director of CNBE-INRS. We welcome inquiries into model expansion and/or development in these species as well. About Woodland Biosciences Woodland BioSciences is a preclinical contract research organization (CRO) providing innovative and customized solutions and consultation to the biotechnology community. The mission of Woodland is to enhance drug development for the most severe cancers, inflammation and other major diseases. Woodland also enters shared-risk ventures through our bioincubator to help advance early molecules to value creation milestones. About CNBE INRS CNBE, located on the INRS campus in Laval, offers high standard preclinical research services to the scientific community and the biotechnology and pharmaceutical industries. Certified by the Canadian Council on Animal Care in Science (CCAC) and the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International) Source: Michael R. Briggs Mario C. Filion President Director Woodland Bioscience CNBE INRS Worcester, MA, USA Laval, Québec, Canada mbriggs@woodlandpharma.com Mario.Filion@ www.woodlandbiosciences.com www.cnbe.inrs.ca End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|